Lung Cancer

Two new FDA approvals for patients with lung cancer and EGFR exon 20 insertion mutations have given the subset its first targeted therapies.

Out of the darkness there is sometimes light, and in South Florida, Dr. Mark Block is a beacon of hope and light for many patients who’ve recently received a diagnosis of cancer.

On this episode of the “Cancer Horizons” podcast, a young mother living with lung cancer shares the story of her cancer diagnosis and describes the once-in-a-lifetime coincidence of learning her neighbor has the same cancer type and mutation.

In an era of trauma, people whose buoyancy elevates both purpose and agency shine like a flashlight in the darkness. During the past year of uncertainty, Dave Bjork was that light for many.

One cancer survivor's garden helped her to cope and stay active during diagnosis, through treatment and into remission.

Studies show that quitting smoking after a lung cancer diagnosis has a huge payoff for patients. Many smoking cessation programs in cancer centers have tools to help patients quit.

The majority of Americans lack understanding of lung cancer’s deadly threat and how it can be screened for, according to new survey data from the American Lung Association. One survivor and one patient stress the importance of learning more about the deadliness of the disease.

Upal Basu Roy has a true gift of being able to think from his heart. He educates the patient community, helps patients navigate the fragmented system, fights for drug access issues in other countries, addresses disparities and supports patient-driven initiatives in research and advocacy.

Lung cancer is a dangerous and often silent killer for the residents of northeast Georgia. For Dr. Arfoosh, lung cancer screening, quick referrals and prompt treatment for people with newly diagnosed lung cancer are at the forefront of his daily work.

After Kelsey Ahmed’s mother, Martha, was diagnosed with stage 4 non-small cell lung cancer, Kelsey and her family got to work raising funds and spreading awareness for the American Lung Association.

Patients who experience side effects due to immune checkpoint inhibitors are 80% more likely to go to the emergency room and have 30% higher monthly medical costs, compared to patients who did not have side effects.

In this episode of CURE’s “Cancer Horizons” podcast, three individuals, who were recognized as CURE Lung Cancer Heroes, spoke about what the honor means to them and bringing the lung cancer community together.

By creating a community of survivors, researchers, physicians and clinicians, The White Ribbon Project — under Heidi Nafman-Onda’s direction — has influenced real change.

When cancer treatments stop working, it is not the end of the line. Most patients with advanced disease will be on continuous therapy, and that means trying different options along the way.

The FDA approval is based on ‘substantial’ disease-free survival results and may ‘drastically’ improve lung cancer survival.

"Dr. Rosenzweig’s commitment to helping patients with lung cancer and mesothelioma is truly heroic," several colleagues write.

These are the powerful stories of real-life heroes in the lung cancer space who persevere with great compassion and teach us to embrace, not avoid, life’s setbacks and challenges.

"Dr. Hossein came to the United States by himself in his teens as a political refugee from the turmoil in Iran," writes a colleague who nominated him for the Lung Cancer Heroes® Award. "Completely on his own and through his hard work, scholarship, initiative and refusal to let things get him down, he went to college and then to medical school."

CURE®’s Lung Cancer Heroes® Award Program celebrates and thanks the heroes who make a difference in the lives of patients with lung cancer.

Treatment with the immunotherapy Opdivo for relapsed, malignant mesothelioma may represent a useful choice for patients with minimal therapy options.

From former New York Islanders hockey player Mike Bossy announcing that he has lung cancer to First Lady Jill Biden emphasizing the importance of breast cancer screenings, here’s what’s happening in the cancer landscape this week.

A company focused on treating underserved patients announced that the first patient with an NTRK fusion was dosed in a phase 2 trial of taletrectinib this summer.

The Food and Drug Administration approved adjuvant Tecentriq for patients with PD-L1—positive, stage 2 to 3A non-small cell lung cancer.

Aileron Therapeutics, Inc. announced the initiation of a clinical trial for ALRN-6924, a treatment for patients with non-small cell lung cancer.

Allison Collins reflects on the genetic testing she underwent after receiving a non-small cell lung cancer diagnosis and describes the treatment options presented to her at that time.